Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its new antibody-drug conjugate, HS-20110, aimed at treating advanced solid tumors. This development marks a significant step in the company’s innovation efforts, potentially impacting its market position.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.